

# The unequal burden of interstitial lung disease mortality in older US adults: a 22-year analysis and projections to 2030

Tong Feng<sup>1</sup>, Pengcheng Zheng<sup>2,3,4#</sup>, Yue Cao<sup>5</sup>, Ding Han<sup>1</sup>, Ran Duan<sup>2,6\*</sup>

<sup>1</sup>Department of Respiratory and Critical Care Medicine, Deyang People's Hospital, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Deyang, China

<sup>2</sup>School of Clinical Medicine, Chengdu Medical College, Chengdu, China

<sup>3</sup>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China

<sup>4</sup>Laboratory of Geriatric Respiratory Diseases of Sichuan Higher Education Institute, Chengdu, China

<sup>5</sup>Department of Cardiology, Affiliated Hospital of Southwest Medical University, China

<sup>6</sup>Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China

**\*Corresponding author:**

Ran Duan

Department of Oncology

The First Affiliated Hospital

of Chengdu Medical College

Chengdu, China

E-mail: 1345295687@qq.com

**Submitted:** 16 March 2026; **Accepted:** 4 June 2026

**Online publication:** 20 August 2026

Arch Med Sci 2026; 22 (4): 1961–1969

DOI: <https://doi.org/10.5114/aoms/224183>

Copyright © 2026 Termedia & Banach

## Abstract

**Introduction:** Interstitial lung disease (ILD) comprises a heterogeneous group of disorders characterized by progressive lung fibrosis, respiratory failure, and substantial mortality, particularly among older adults. While prior studies have described historical ILD mortality trends, comprehensive analyses incorporating future projections, detailed geographic disparities, and socioeconomic variation remain limited.

**Material and methods:** We analyzed CDC WONDER underlying-cause-of-death data for US adults aged ≥ 65 years from 1999 to 2020. ILD deaths were identified using ICD-10 code J84, and age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 US standard population. Joinpoint regression was used to identify turning points in mortality trends, autoregressive integrated moving average (ARIMA) modeling was used to project AAMRs through 2030, and Socio-demographic Index (SDI)-based correlation and frontier analyses were used to evaluate geographic and socioeconomic disparities in ILD mortality.

**Results:** A total of 305,452 ILD deaths were recorded among US adults aged ≥ 65 years, with an overall AAMR of 33.45 per 100,000 population. Mortality increased significantly from 1999 to 2006 and then stabilized through 2020, with ARIMA models projecting continued stability through 2030. Significant disparities persisted, with mortality rates highest among males, American Indian or Alaska Native populations, Hispanic or Latino individuals, and residents of Western and Midwestern states. State-level analyses showed that lower SDI was generally associated with higher AAMR, with several states exhibiting excess mortality relative to their socioeconomic development levels.

**Conclusions:** Although ILD mortality among older US adults stabilized after the mid-2000s and is projected to remain stable through 2030, substantial disparities persist across sex, race/ethnicity, geography, and socioeconomic context. These findings suggest that future reductions in ILD mortality may depend less on broad population-level declines and more on targeted strategies focused on high-burden groups and regions.

**Key words:** interstitial lung disease, mortality trends, older adults, socio-demographic disparities, Joinpoint regression, ARIMA projection, frontier analysis.

## Introduction

Interstitial lung disease (ILD) comprises a heterogeneous group of pulmonary disorders characterized by inflammation, fibrosis, progressive respiratory impairment, and increased mortality, particularly among older adults [1–3]. While age-adjusted mortality rates (AAMR) showed relative stability before the COVID-19 pandemic, sharp inequalities were evident across racial groups, sexes, and geographic regions. Mortality was highest among older populations, especially individuals aged 85 years and older [4]. On a global scale, data from the 2019 Global Burden of Disease (GBD) study indicate an age-standardized prevalence rate for ILD (encompassing pulmonary sarcoidosis) of roughly 57.62 cases per 100,000 people. The corresponding global mortality rate was 2.17 per 100,000, reflecting a slow but consistent increase over time [5].

Older adults are particularly vulnerable to ILD mortality because age-related declines in pulmonary function, multimorbidity, frailty, and reduced tolerance to diagnostic and therapeutic interventions can delay diagnosis and worsen outcomes [6, 7]. Despite this elevated risk, important public health gaps remain, including limited understanding of long-term mortality trends, future projections, and demographic, geographic, and socioeconomic disparities in ILD mortality among older adults.

Although prior CDC WONDER-based studies have described historical ILD mortality trends, they have rarely integrated forecasting with detailed geographic and socioeconomic disparity analyses. As a result, it remains difficult to identify underperforming regions with potentially preventable excess mortality or to anticipate future public health needs, limiting the ability to inform targeted policy and resource allocation [4].

Clarifying the demographic (e.g., age, sex, race) and geographic distribution patterns of ILD-associated fatalities enables the pinpointing of high-risk groups – such as older males, specific racial and ethnic populations, and regions with a lower Socio-demographic Index (SDI). This knowledge is critical for guiding resource distribution, implementing early detection programs, and developing targeted interventions aimed at reducing health inequities and improving patient outcomes [8, 9].

This study aims to fill these gaps by applying advanced statistical methods, including Joinpoint regression, ARIMA forecasting, and frontier analysis, to comprehensively assess ILD mortality trends, disparities, and projected future burden among US adults aged  $\geq 65$  years.

## Material and methods

This ecological study used population-level mortality data to examine trends, disparities, and

projections of ILD mortality among U.S. adults aged  $\geq 65$  years.

### Data sources and case definition

Mortality data were obtained from the CDC WONDER underlying cause-of-death database for U.S. adults aged  $\geq 65$  years from 1999 to 2020. ILD deaths were identified using ICD-10 code J84 when it was listed as the underlying cause of death. Thus, this study captures deaths primarily attributed to ILD rather than deaths in which ILD was recorded only as a contributing condition. Age-adjusted mortality rates were calculated per 100,000 population using the 2000 U.S. standard population. Stratified analyses were conducted by sex, age group, race, Hispanic origin, census region, state, and urbanization level according to available CDC WONDER categories.

### Handling of missing data

For Hispanic origin, deaths reported as “Not Stated” in CDC WONDER were included in the overall “All” totals and rates but were excluded from Hispanic origin-specific counts and rates because no corresponding population denominator is available for this category. For race, NCHS applies a bridging procedure to impute multiple-race reports to a single-race category based on combinations of race, Hispanic origin, sex, and age, thereby maintaining comparability across the study period. Records with completely unknown race were rare and were handled similarly to other “Not Stated” categories. Urbanization classification was based on the decedent’s county of residence using the NCHS Urban-Rural Classification Scheme, such as metro and nonmetro categories. Because each U.S. county is assigned to an urbanization category, this variable has near-complete coverage; records with missing urbanization information, if present, were retained in overall totals but not included in stratum-specific urbanization analyses.

### Study design and population

This population-based study assessed ILD mortality among US adults aged  $\geq 65$  years from 1999 to 2020. Analyses were conducted using aggregate-level mortality data from all US states and the District of Columbia. Deaths and AAMRs were stratified by sex, age group, race/ethnicity, year, geographic region, and urbanization status. Age adjustment minimized the influence of changes in population age structure over time and allowed comparisons across demographic and geographic subgroups.

## Statistical analysis

### Temporal trends (Joinpoint regression)

Joinpoint regression was used to identify temporal changes in ILD mortality rates and to pinpoint time points (“joinpoints”) at which trends significantly changed direction, allowing for a more precise characterization of mortality dynamics over time. This method detects points where the linear slope of the trend undergoes statistically significant changes, calculates the annual percent change (APC), and identifies key turning points [10, 11]. This analysis enables us to determine periods of significant increase or decrease in ILD mortality rates, thereby providing deeper insights into the temporal patterns of mortality and potential factors influencing these trends.

### ARIMA forecasting analysis

Autoregressive integrated moving average (ARIMA) modeling was used to forecast ILD mortality rates through 2030, providing a forward-looking estimate of future burden based on historical patterns. The model was based on annual data from 1999–2020, with parameters optimized via autocorrelation functions and the BIC [12, 13].

Time-series forecasting was performed using ARIMA models, which are well suited for modeling temporal trends and autocorrelation in relatively short annual mortality time series. Alternative approaches, including exponential smoothing (ETS) and Prophet models, were considered; however, given the limited length of the annual data and the absence of pronounced seasonal patterns, ARIMA was selected as a more parsimonious and interpretable approach. Model performance was evaluated by comparing observed and fitted values, which demonstrated good agreement ( $r = 0.789$ ,  $p < 0.001$ ). Residual diagnostics, including Q–Q plots, autocorrelation function (ACF), and partial autocorrelation function (PACF), indicated that residuals were approximately normally distributed and exhibited no significant autocorrelation. The Ljung–Box test further confirmed that residuals behaved as white noise ( $Q = 4.954$ ,  $p = 0.292$ ), supporting model adequacy.

### SDI correlation analysis

To examine the relationship between socioeconomic development and ILD mortality, we conducted correlation analyses between mortality rates and the SDI, a composite measure reflecting income, education, and fertility. This analysis provides insight into how ILD mortality varies across levels of socioeconomic development.

## Frontier analysis

The SDI was used to characterize state-level socioeconomic development. SDI is a composite indicator ranging from 0 to 1, derived from income per capita, average educational attainment, and fertility rate; higher SDI values indicate higher socioeconomic development, whereas lower values indicate lower development. We quantified the association between state-level SDI and AAMR to identify states with excess mortality relative to their development level.

Frontier analysis was applied to estimate the lowest potentially achievable AAMR at a given SDI level and to identify states deviating from this benchmark. The frontier model specified state-level AAMR as the dependent variable and SDI as the main explanatory variable, with a composed error term including random statistical noise and a one-sided non-negative inefficiency component representing excess mortality above the frontier. The model was fitted using Stata version 18.0 with the frontier command. States closer to the estimated frontier were interpreted as having lower-than-expected mortality for their SDI level, whereas states farther from the frontier were considered to have greater potentially reducible mortality burden.

## Results

### Demographic and geographic disparities in ILD mortality

From 1999 to 2020, a total of 305,452 ILD deaths occurred among US adults aged  $\geq 65$  years, corresponding to an overall age-adjusted mortality rate of 33.45 per 100,000 population. Substantial disparities were observed across demographic and geographic groups. Mortality was markedly higher among males than females, approaching a two-fold difference. Among racial groups, American Indian or Alaska Native individuals experienced the highest mortality burden, whereas Black or African American individuals had the lowest rates. Geographic variation was also evident, with higher mortality concentrated in the West and Midwest. Nonmetropolitan areas showed only a modestly higher mortality burden than metropolitan areas. Detailed subgroup-specific estimates are presented in Table I.

### State-level geographic variation

State-level AAMRs among older adults showed substantial geographic heterogeneity from 1999 to 2020. Higher mortality burdens were concentrated in several northern, western, and Appalachian states, whereas lower rates were observed in the District of Columbia and some coastal states. These findings indicate that the burden

**Table I.** Demographic and geographic characteristics of deaths due to interstitial lung disease among adults aged  $\geq 65$  years in the United States, 1999–2020. Deaths/population indicates the number of ILD deaths and the corresponding population size. AAMR is expressed per 100,000 population and was age-adjusted using the 2000 U.S. standard population

| Variable                         | Deaths/population | AAMR (95% CI)        |
|----------------------------------|-------------------|----------------------|
| Overall                          | 305452/928476665  | 33.45 (33.34, 33.57) |
| Census region                    |                   |                      |
| Midwest                          | 73303/207118111   | 35.28 (35.02, 35.53) |
| Northeast                        | 54889/179714300   | 30.07 (29.81, 30.32) |
| South                            | 109082/343442253  | 33.02 (32.82, 33.22) |
| West                             | 68178/198202001   | 35.36 (35.09, 35.63) |
| Sex                              |                   |                      |
| Female                           | 143730/527632126  | 26.22 (26.08, 26.35) |
| Male                             | 161722/400844539  | 44.06 (43.84, 44.28) |
| Hispanic origin                  |                   |                      |
| Hispanic or Latino               | 22665/65124722    | 38.05 (37.55, 38.55) |
| Not Hispanic or Latino           | 282339/863351943  | 33.03 (32.91, 33.16) |
| Race                             |                   |                      |
| American Indian or Alaska Native | 2197/6051868      | 41.67 (39.88, 43.46) |
| Asian or Pacific Islander        | 7695/35919615     | 23.75 (23.21, 24.28) |
| Black or African American        | 12811/83274492    | 16.28 (15.99, 16.56) |
| White                            | 282749/803230690  | 35.37 (35.24, 35.5)  |
| Urbanization                     |                   |                      |
| Metro                            | 249500/760496648  | 33.33 (33.2, 33.46)  |
| Nonmetro                         | 55952/167978547   | 33.97 (33.68, 34.25) |

ILD – interstitial lung disease, AAMR – age-adjusted mortality rate, CI – confidence interval.

of ILD mortality was unevenly distributed across the country. Detailed state-specific estimates are provided in Supplementary Table S1 and Figure 1.

### Sex- and age-specific trends in mortality rates

Mortality rates increased markedly with advancing age in both 1999 and 2020, and males consistently exhibited higher rates than females across all age groups. The sex disparity was most pronounced in the oldest age group, indicating that advanced age and male sex were both associated with a greater mortality burden. Across the study period, mortality in the 65–74-year group remained relatively stable or declined slightly, whereas rates in the older age groups increased for much of the period before showing a modest decline near the end of follow-up. These age- and sex-specific patterns, together with their temporal changes, are summarized in Supplementary Figures S2 and S3 and Supplementary Table SII.


### Long-term trends and age distribution of ILD burden

From 1999 to 2020, the burden of ILD mortality among older US adults increased substantially in

absolute terms, with annual deaths nearly doubling over the study period and peaking in 2019 before a slight decline in 2020. The AAMR also rose overall and then leveled off toward the end of the study period. Throughout the follow-up, males consistently carried a higher mortality burden than females, and the distribution of deaths gradually shifted toward the oldest age group. Together, these findings suggest that population aging contributed importantly to the growing burden of ILD mortality, even as age-adjusted rates stabilized in later years. These patterns are shown in Supplementary Figures S4 and S5 and Supplementary Table SIII.

### Trend analysis and inflection points

Joinpoint regression identified a significant increase in overall age-adjusted ILD mortality from 1999 to 2006 (APC 2.73%,  $p < 0.001$ ), followed by a non-significant plateau through 2020. Sex-stratified analyses showed a similar pattern in both females and males, with an early increase followed by relative stabilization. These results indicate that the mortality burden rose in the early years of the study period but did not continue increasing thereafter. Detailed APC es-



**Figure 1.** State-level age-adjusted mortality rates for interstitial lung disease among U.S. adults aged  $\geq 65$  years, 1999–2020. Age-adjusted mortality rates are expressed per 100,000 population and were calculated using the 2000 U.S. standard population

timates are provided in Figure 2 and Supplementary Table SIV.


#### Projections of future ILD mortality trajectories

ARIMA modeling projected that age-adjusted ILD mortality rates will remain broadly stable from 2021 through 2030 overall and in both sexes. Male mortality is expected to remain consistently higher than female mortality throughout the projection period. Although prediction intervals widened over time, reflecting increasing uncertainty in longer-term forecasts, no clear upward


or downward trend was anticipated. Detailed projected estimates are presented in Figure 3 and Supplementary Table SV.

#### Socio-demographic influences and efficiency frontiers


State-level analyses showed a non-linear association between socio-demographic development and ILD mortality, with mortality generally tending to decline as SDI increased. Frontier analysis further revealed substantial heterogeneity among states with similar SDI levels, suggesting that part of the observed burden may be potentially reduc-



**Figure 2.** Joinpoint regression analysis of age-adjusted mortality rate trends for interstitial lung disease among U.S. adults aged  $\geq 65$  years, 1999–2020. Panel **A** shows the overall trend, and Panel **B** shows trends stratified by sex. AAMRs are expressed per 100,000 population



**Figure 3.** Observed and autoregressive integrated moving average (ARIMA)-predicted age-adjusted mortality rates for interstitial lung disease among U.S. adults aged ≥ 65 years through 2030. Panel A shows the overall observed and projected age-adjusted mortality rates (AAMRs), and Panel B shows sex-specific observed and projected AAMRs. Shaded areas represent 95% prediction intervals



**Figure 4.** Distribution of interstitial lung disease mortality burden across state-level Socio-demographic Index (SDI) levels among U.S. adults aged ≥ 65 years. Each point represents a state-year estimate. Age-adjusted mortality rates (AAMRs) are expressed per 100,000 population

ible. States located far from the frontier appeared to have greater room for improvement relative to their socioeconomic context. These findings are illustrated in Figures 4 and 5.

### Discussion


Because this study was based on an ecological design using aggregate mortality data, the

observed temporal, demographic, geographic, and socioeconomic patterns should be interpreted as population-level associations, and causal inferences at the individual level cannot be drawn.

The plateau: a story of progress and persistent challenges: In this national analysis of ILD mortality among U.S. adults aged 65 years and older from 1999 to 2020, we observed an early increase in age-adjusted mortality followed by a prolonged

plateau after the mid-2000s. This pattern may reflect improvements in disease recognition, diagnostic coding, and access to high-resolution imaging during the earlier study period [14, 15]. However, because our analysis was based on aggregate mortality data, we cannot determine the relative contribution of these factors or establish causality. The subsequent stabilization may suggest progress in clinical management, including broader awareness of fibrotic ILD and the availability of antifibrotic therapies for selected ILD subtypes [16–18]. This interpretation should be considered hypothesis-generating, as the present dataset did not include information on imaging use, ILD subtype, treatment uptake, disease severity, or individual-level clinical characteristics. However, the absence of a sustained decline indicates that major challenges remain, including delayed diagnosis, variable access to specialist care, and limited treatment options for non-IPF fibrotic ILD. Our ARIMA projections further suggest that ILD mortality rates among older adults may remain stable through 2030, highlighting the need for continued efforts to improve prevention, early detection, and treatment delivery.

**Sex, race, and place: unpacking persistent disparities:** Marked disparities by sex, race/ethnicity, and geography were evident. Males consistently experienced higher mortality than females, particularly in the oldest age groups. This sex differential has been repeatedly documented in ILD cohorts and may stem from higher cumulative occupational and environmental exposures (e.g., asbestos, silica, organic dusts), historically greater smoking rates among male cohorts, hormonal influences on fibrogenesis, or sex-specific differences in immune response and disease progression [19–21]. Racial and ethnic variations further highlighted inequities: American Indian or Alaska Native individuals displayed the highest AAMR (41.67 per 100,000), followed by White (35.37) groups, whereas Black or African American (16.28) and Asian or Pacific Islander (23.75) populations had substantially lower rates [22]. The elevated burden among Native Americans likely reflects compounded risks from socioeconomic disadvantage, residential environmental exposures (e.g., biomass fuel, mining), and restricted access to specialized pulmonary care [23, 24]. The relatively high rates in Hispanic individuals contrast with lower mortality patterns observed in other chronic conditions (the “Hispanic paradox”) and may indicate differences in diagnostic practices, regional occupational hazards, or underascertainment in non-Hispanic groups. These findings should be interpreted cautiously, because death certificate data cannot fully account for differences in diagnosis, coding,



**Figure 5.** Frontier analysis of the relationship between state-level Socio-demographic Index (SDI) and age-adjusted mortality rates for interstitial lung disease among U.S. adults aged  $\geq 65$  years, 2020. The plot displays 2020 state-level age-adjusted mortality rates (AAMRs) and SDI values for each state across the study period. The frontier represents the lowest theoretically achievable AAMR at a given SDI level. States farther from the frontier indicate greater excess mortality relative to their socioeconomic development level

healthcare access, environmental exposures, or comorbidity burden. Nonetheless, the observed disparities highlight the need for more detailed studies using individual-level clinical and socioeconomic data.

**The frontier: identifying states with excess mortality:** Geographically, AAMR showed substantial variation across census regions and states, with the highest rates observed in the West (35.36) and Midwest (35.28). Notable high outliers included Maine (45.01), Idaho (44.67), and Utah (42.91). Distribution and frontier analyses demonstrated an inverse relationship between state-level SDI and AAMR. States such as Nevada, Oklahoma, New York, Florida, and Connecticut closely approximated the mortality frontier, indicating optimized ILD outcomes relative to their socioeconomic context. In contrast, distant outliers, including Maine, Vermont, South Dakota, Utah, and Oregon, consistently demonstrated substantially higher mortality than expected given their SDI levels.

These underperforming states, many of which are predominantly rural, likely face multiple modifiable barriers including limited access to specialized pulmonary care, fewer ILD centers, longer travel distances to academic medical centers, and delayed specialist referrals. Additional contributing factors may include higher environmental and occupational exposures (e.g., mining, agriculture, or wood dust in northern New England and Pacific Northwest states), diagnostic delays due to lower clinician awareness or limited availability of

high-resolution CT, and challenges in implementing antifibrotic therapies in resource-constrained settings. Nonmetro areas also exhibited marginally higher AAMR than metro areas (33.97 vs. 33.33), further underscoring the role of urbanization and healthcare resource distribution.

These findings highlight substantial preventable mortality burden and point to clear policy directions. Targeted interventions worth testing in lagging states include: expanding tele-pulmonology networks and mobile diagnostic services, establishing regional ILD referral hubs, incentivizing specialist retention in rural areas, enhancing environmental surveillance and exposure mitigation programs, and implementing clinician education campaigns on early ILD recognition. Such state-specific strategies could meaningfully reduce the efficiency gap identified by frontier analysis and advance health equity in ILD care.

The shifting age composition of ILD deaths – toward greater contribution from the  $\geq 85$ -year stratum – mirrors broader demographic aging and underscores the vulnerability of the oldest old, in whom comorbidities, frailty, and therapeutic intolerance amplify mortality risk [25]. ARIMA forecasts of sustained stability, coupled with widening prediction intervals, highlight that the absolute number of ILD deaths may rise with population aging despite stable mortality rates, underscoring the need for continued advances in prevention, early detection, and treatment.

**Implications for policy and practice:** These findings have several implications. First, stable mortality rates should not be interpreted as evidence that the burden of ILD is diminishing, particularly as the U.S. older adult population continues to grow. Second, persistent disparities suggest the need for targeted strategies in high-burden populations and regions, including improved access to ILD specialty care, earlier recognition of fibrotic lung disease, and equitable implementation of evidence-based therapies. Third, state-level geographic differences support the value of regional surveillance and resource planning. Finally, the combination of mortality trend analysis, forecasting, and frontier benchmarking may help public health agencies identify areas where intervention could yield the greatest reduction in preventable ILD deaths.

**Strengths and limitations:** Several limitations should be acknowledged. First, this study was based on an ecological, state-level analysis using aggregated mortality data; therefore, the findings cannot be used to infer individual-level risk or establish causal relationships between socio-demographic factors, geographic characteristics, and ILD mortality. Second, ILD deaths were identified using ICD-10 code J84 from death certificate data,

which may be subject to misclassification, underreporting, or coding bias. In older adults with multiple comorbidities, ILD may not always be recorded consistently as a contributing or underlying cause of death. Third, the ICD-10 J84 category includes a heterogeneous group of ILD, and the database does not allow reliable differentiation among ILD subtypes, such as idiopathic pulmonary fibrosis, connective tissue disease-associated ILD, hypersensitivity pneumonitis, or occupational/environmental ILD. As a result, subtype-specific mortality patterns and treatment-related effects could not be evaluated. Fourth, the study lacked individual-level information on smoking history, occupational and environmental exposures, comorbidities, medication use, healthcare access, and disease severity, which limits mechanistic interpretation of the observed disparities. Finally, although frontier and SDI analyses are useful for benchmarking state-level variation, they should be interpreted as hypothesis-generating tools rather than evidence of causal underperformance by specific states. The decline in ILD AAMR observed in 2020 was interpreted with caution. This decrease may not necessarily represent a true reduction in ILD mortality, as the COVID-19 pandemic may have influenced mortality patterns through competing causes of death, changes in healthcare utilization, delayed diagnosis or treatment, and potential shifts in death certificate coding. In particular, some deaths among older adults with ILD may have been attributed primarily to COVID-19 or other acute respiratory complications rather than ILD. Given the aggregate nature of CDC WONDER data, we were unable to distinguish these mechanisms or quantify the direct contribution of COVID-19 to the 2020 decline. Future studies incorporating post-2020 data and individual-level clinical information are warranted to clarify the pandemic's long-term impact on ILD mortality trends.

In conclusion, although ILD age-adjusted mortality rates in older US adults have stabilized since the mid-2000s, profound disparities persist by sex, race/ethnicity, geography, and SDI. Males experience nearly twofold higher mortality, while American Indian/Alaska Native and Hispanic populations, along with several rural and low-SDI states, bear a disproportionately high burden. Frontier analysis highlights substantial preventable mortality even after accounting for socioeconomic context. With the continued aging of the US population, the absolute number of ILD deaths is expected to remain substantial through 2030. Targeted interventions in high-risk populations and underperforming states are essential to reduce inequities and alleviate the growing public health burden of ILD.

## Acknowledgments

Tong Feng and Pengcheng Zheng contributed equally to this work and should be considered co-first authors.

## Availability of data and materials

The mortality data are publicly available on the internet for data users and researchers throughout the world (<https://wonder.cdc.gov/>).

## Funding

This study was funded by the 2025 Sichuan Province Clinical Key Specialty Construction Project (Project No. YS000177).

## Ethical approval

This study utilized publicly available, de-identified, and aggregated data from the CDC WONDER database, which does not contain identifiable individual-level information. As such, institutional review board (IRB) approval and informed consent from participants were not required in accordance with national regulations and institutional guidelines for secondary data analysis of public health datasets.

## Conflict of interest

The authors declare no conflict of interest.

## References

1. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. *Lancet* 2022; 400: 769-86.
2. Guler SA, Corte TJ. Interstitial lung disease in 2020: a history of progress. *Clin Chest Med* 2021; 42: 229-39.
3. Ochman M, Urlik M, Tatoj Z, et al. Retrospective cohort study of patients qualified for lung transplantation due to idiopathic pulmonary fibrosis - single-centre experience. *Arch Med Sci* 2020; 16: 621-6.
4. Leary C, Bine C, Baral N, et al. Trends in interstitial lung disease and the COVID-19 pandemic in the United States from 1999 to 2022. *Respir Res* 2025; 26: 277.
5. Zeng Q, Jiang D. Global trends of interstitial lung diseases from 1990 to 2019: an age-period-cohort study based on the Global Burden of Disease study 2019, and projections until 2030. *Front Med* 2023; 10: 1141372.
6. Patterson KC, Shah RJ, Porteous MK, et al. Interstitial lung disease in the elderly. *Chest* 2017; 151: 838-44.
7. Meyer KC. Interstitial lung disease in the elderly: pathogenesis, diagnosis and management. *Sarcoidosis Vasc Diffuse Lung Dis* 2011; 28: 3-17.
8. Tikellis G, Holland AE. Health disparities and associated social determinants of health in interstitial lung disease: a narrative review. *Eur Respir Rev* 2025; 34: 240176.
9. Goobie GC, Ryerson CJ, Johansson KA, et al. Neighborhood-level disadvantage impacts on patients with fibrotic interstitial lung disease. *Am J Respir Crit Care Med* 2022; 205: 459-67.
10. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med* 2000; 19: 335-51.
11. Kim HJ, Chen HS, Byrne J, Wheeler B, Feuer EJ. Twenty years since Joinpoint 1.0: Two major enhancements, their justification, and impact. *Stat Med* 2022; 41: 3102-30.
12. Newbold P. ARIMA model building and the time series analysis approach to forecasting. *J Forecast* 1983; 2: 23-35.
13. Jian Y, Zhu D, Zhou D, et al. ARIMA model for predicting chronic kidney disease and estimating its economic burden in China. *BMC Public Health* 2022; 22: 2456.
14. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med* 2018; 6: 138-53.
15. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. *N Engl J Med* 2018; 378: 1811-23.
16. Lancaster LH, de Andrade JA, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. *Eur Respir Rev* 2017; 26: 170057.
17. Lamb YN. Nintedanib: a review in fibrotic interstitial lung diseases. *Drugs* 2021; 81: 575-86.
18. Yüksel A, Nezalzova P, Ulubay G. Efficacy of antifibrotics in slowing FVC and DLCO decline in progressive pulmonary fibrosis: a real world experience. *Arch Med Sci* 2025. DOI: <https://doi.org/10.5114/aoms/210329>.
19. Serrano Gotarredona MP, Navarro Herrero S, Gómez Izquierdo L, Rodríguez Portal JA. Smoking-related interstitial lung disease. *Radiologia* 2022; 64 Suppl 3: 277-89.
20. Bellou V, Belbasis L, Evangelou E. Tobacco smoking and risk for pulmonary fibrosis: a prospective cohort study from the UK Biobank. *Chest* 2021; 160: 983-93.
21. Pandit P, Perez RL, Roman J. Sex-based differences in interstitial lung disease. *Am J Med Sci* 2020; 360: 467-73.
22. Adegunsoye A, Oldham JM, Bellam SK, et al. African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. *Eur Respir J* 2018; 51: 1800255.
23. Swigris JJ, Olson AL, Huie TJ, et al. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. *Respir Med* 2012; 106: 588-93.
24. Adegunsoye A, Freiheit E, White EN, et al. Evaluation of pulmonary fibrosis outcomes by race and ethnicity in US adults. *JAMA Netw Open* 2023; 6: e232427.
25. Spagnolo P, Cordier JF, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. *Eur Respir J* 2016; 47: 1535-58.